UTHR Quote, Financials, Valuation and Earnings

Catalyst Pharmaceuticals, Inc. has a net margin of 42.36% compared to United Therapeutics Corp.'s net margin of 35.57%. United Therapeutics Corp.'s return on equity of 19.2% beat Catalyst Pharmaceuticals, Inc.'s return on equity of 27.48%.

United Therapeutics Corp. has a consensus price target of $518.25, signalling upside risk potential of 2.19%. On the other hand Catalyst Pharmaceuticals, Inc. has an analysts' consensus of $34.86 which suggests that it could grow by 43.15%. Given that Catalyst Pharmaceuticals, Inc. has higher upside potential than United Therapeutics Corp., analysts believe Catalyst Pharmaceuticals, Inc. is more attractive than United Therapeutics Corp..

United Therapeutics Corp. has a beta of 0.861, which suggesting that the stock is 13.874% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals, Inc. has a beta of 0.685, suggesting its less volatile than the S&P 500 by 31.5%.

United Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. United Therapeutics Corp. pays -- of its earnings as a dividend. Catalyst Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

United Therapeutics Corp. quarterly revenues are $799.5M, which are larger than Catalyst Pharmaceuticals, Inc. quarterly revenues of $148.4M. United Therapeutics Corp.'s net income of $338.7M is higher than Catalyst Pharmaceuticals, Inc.'s net income of $52.8M. Notably, United Therapeutics Corp.'s price-to-earnings ratio is 19.22x while Catalyst Pharmaceuticals, Inc.'s PE ratio is 14.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics Corp. is 7.82x versus 5.35x for Catalyst Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Gilead Sciences, Inc. has a net margin of 42.36% compared to United Therapeutics Corp.'s net margin of 39.21%. United Therapeutics Corp.'s return on equity of 19.2% beat Gilead Sciences, Inc.'s return on equity of 41.48%.

United Therapeutics Corp. has a consensus price target of $518.25, signalling upside risk potential of 2.19%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $132.38 which suggests that it could grow by 6.16%. Given that Gilead Sciences, Inc. has higher upside potential than United Therapeutics Corp., analysts believe Gilead Sciences, Inc. is more attractive than United Therapeutics Corp..

United Therapeutics Corp. has a beta of 0.861, which suggesting that the stock is 13.874% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.175%.

United Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences, Inc. offers a yield of 2.53% to investors and pays a quarterly dividend of $0.79 per share. United Therapeutics Corp. pays -- of its earnings as a dividend. Gilead Sciences, Inc. pays out 805.23% of its earnings as a dividend.

United Therapeutics Corp. quarterly revenues are $799.5M, which are smaller than Gilead Sciences, Inc. quarterly revenues of $7.8B. United Therapeutics Corp.'s net income of $338.7M is lower than Gilead Sciences, Inc.'s net income of $3.1B. Notably, United Therapeutics Corp.'s price-to-earnings ratio is 19.22x while Gilead Sciences, Inc.'s PE ratio is 19.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics Corp. is 7.82x versus 5.39x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Insmed, Inc. has a net margin of 42.36% compared to United Therapeutics Corp.'s net margin of -259.95%. United Therapeutics Corp.'s return on equity of 19.2% beat Insmed, Inc.'s return on equity of -193.23%.

United Therapeutics Corp. has a consensus price target of $518.25, signalling upside risk potential of 2.19%. On the other hand Insmed, Inc. has an analysts' consensus of $214.78 which suggests that it could grow by 20.84%. Given that Insmed, Inc. has higher upside potential than United Therapeutics Corp., analysts believe Insmed, Inc. is more attractive than United Therapeutics Corp..

United Therapeutics Corp. has a beta of 0.861, which suggesting that the stock is 13.874% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.015, suggesting its more volatile than the S&P 500 by 1.49%.

United Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. United Therapeutics Corp. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.

United Therapeutics Corp. quarterly revenues are $799.5M, which are larger than Insmed, Inc. quarterly revenues of $142.3M. United Therapeutics Corp.'s net income of $338.7M is higher than Insmed, Inc.'s net income of -$370M. Notably, United Therapeutics Corp.'s price-to-earnings ratio is 19.22x while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics Corp. is 7.82x versus 75.70x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 42.36% compared to United Therapeutics Corp.'s net margin of 21.47%. United Therapeutics Corp.'s return on equity of 19.2% beat Johnson & Johnson's return on equity of 33.27%.

United Therapeutics Corp. has a consensus price target of $518.25, signalling upside risk potential of 2.19%. On the other hand Johnson & Johnson has an analysts' consensus of $209.29 which suggests that it could grow by 0.8%. Given that United Therapeutics Corp. has higher upside potential than Johnson & Johnson, analysts believe United Therapeutics Corp. is more attractive than Johnson & Johnson.

United Therapeutics Corp. has a beta of 0.861, which suggesting that the stock is 13.874% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.296%.

United Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.48% to investors and pays a quarterly dividend of $1.30 per share. United Therapeutics Corp. pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

United Therapeutics Corp. quarterly revenues are $799.5M, which are smaller than Johnson & Johnson quarterly revenues of $24B. United Therapeutics Corp.'s net income of $338.7M is lower than Johnson & Johnson's net income of $5.2B. Notably, United Therapeutics Corp.'s price-to-earnings ratio is 19.22x while Johnson & Johnson's PE ratio is 20.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics Corp. is 7.82x versus 5.46x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.